|
|
Blood, 1 April 2008, Vol. 111, No. 7, pp. 3439-3441.
Prepublished online as a Blood First Edition Paper on January 14, 2008; DOI 10.1182/blood-2007-09-112052.
Previous Article | Table of Contents | Next Article 
HEMATOPOIESIS AND STEM CELLS
Brief Report
Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab
Halvard Bonig1,
Annette Wundes2,
Kai-Hsin Chang1,
Sylvia Lucas3, and
Thalia Papayannopoulou1
Departments of1 Medicine/Hematology,
2 Rehabilitation Medicine, and
3 Neurology, University of Washington, Seattle
Blockade of CD49d-mediated lymphocyte trafficking has been used therapeutically for certain autoimmune diseases, such as multiple sclerosis (MS). In addition to negative effects on the trafficking of mature lymphocytes to sites of inflammation, CD49d blockade in mice and monkeys rapidly mobilizes hematopoietic stem/progenitor cells (HSPCs) capable of short- and long-term engraftment. Here we aimed to ascertain the effects of treatment with antifunctional anti-CD49d antibody in humans (MS patients receiving infusions of the CD49d-blocking antibody natalizumab) on levels of circulating HSPCs after a single dose of antibody or after long-term treatment. On average, 6-fold elevated levels of circulating CD34+ cells and colony-forming unit-culture (CFU-C) were achieved within 1 day of the first dose of natalizumab, and similar levels were continuously maintained under monthly natalizumab infusions. The blood of natalizumab-treated subjects also contained SCID-repopulating cells. The fate of these circulating HSPCs and their clinical relevance for MS patients remains to be determined.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Articles in Blood Online:
-
About multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors
- Carine Vuaillat, Géraldine Androdias, Nathalie Davoust, and Serge Nataf
Blood 2008 112: 208-209.
[Full Text]
[PDF]
-
Response: More about multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors
- Halvard Bonig, Annette Wundes, and Thalia Papayannopoulou
Blood 2008 112: 209-210.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
E. O. Major
Reemergence of PML in Natalizumab-Treated Patients -- New Cases, Same Concerns
N. Engl. J. Med.,
September 10, 2009;
361(11):
1041 - 1043.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Soler, T. Chapman, L.-L. Yang, T. Wyant, R. Egan, and E. R. Fedyk
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-{alpha}4{beta}7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
J. Pharmacol. Exp. Ther.,
September 1, 2009;
330(3):
864 - 875.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Ramirez, M. P. Rettig, G. L. Uy, E. Deych, M. S. Holt, J. K. Ritchey, and J. F. DiPersio
BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells
Blood,
August 13, 2009;
114(7):
1340 - 1343.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. N. Abboud
Another nail in the AML coffin
Blood,
June 11, 2009;
113(24):
6045 - 6046.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. R. Carson, A. M. Evens, E. A. Richey, T. M. Habermann, D. Focosi, J. F. Seymour, J. Laubach, S. D. Bawn, L. I. Gordon, J. N. Winter, et al.
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Blood,
May 14, 2009;
113(20):
4834 - 4840.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. V. Kurtova, A. T. Tamayo, R. J. Ford, and J. A. Burger
Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting
Blood,
May 7, 2009;
113(19):
4604 - 4613.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Wiendl and R. Hohlfeld
Multiple sclerosis therapeutics: Unexpected outcomes clouding undisputed successes
Neurology,
March 17, 2009;
72(11):
1008 - 1015.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Krumbholz, I. Meinl, T. Kumpfel, R. Hohlfeld, and E. Meinl
Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis
Neurology,
October 21, 2008;
71(17):
1350 - 1354.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. D. Isaacs
Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future
Rheumatology,
October 1, 2008;
47(10):
1461 - 1468.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Vuaillat, G. Androdias, N. Davoust, and S. Nataf
About multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors
Blood,
July 1, 2008;
112(1):
208 - 209.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Bonig, A. Wundes, and T. Papayannopoulou
Response: More about multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors
Blood,
July 1, 2008;
112(1):
209 - 210.
[Full Text]
[PDF]
|
 |
|
|
|